title: The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy.
abstract: Allergen-specific immunotherapy (ASIT) has been used for years to treat dogs with atopic dermatitis (AD) and humans with atopic diseases. The efficacy of ASIT has been well documented for humans with respiratory atopic diseases and stinging insect allergy, but its effectiveness seems more controversial for patients with AD. In spite of insufficient evidence derived from randomized controlled trials, multiple open studies and a large body of clinical observations suggest that ASIT is effective in controlling the clinical signs of dogs with AD. As a result of the scarcity of evidence from controlled trials, the true efficacy of ASIT, and the optimal protocols for allergen dose and frequency of injection are currently unknown. Allergen-specific immunotherapy nevertheless may be included in the treatment of canine AD because of its potential advantages and limited disadvantages compared to other forms of therapy. There is no evidence, however, for the preference of any specific treatment protocol. The predictive value of historical, clinical and immunologic features related to the efficacy of ASIT in dogs with AD are discussed in this paper. Adverse reactions, and the requirements for monitoring of patients receiving ASIT, then are reviewed and detailed. Finally, this review highlights aspects of ASIT where further research and controlled studies are needed.
authors.affiliation: Animal Dermatology Clinic, San Diego, CA 92111, USA. itchypet@aol.com
authors.forename: C E
authors.initials: CE
authors.lastname: Griffin
authors.forename: A
authors.initials: A
authors.lastname: Hillier
mesh_terms: D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D002986:Clinical Trials as Topic / Q000662:veterinary; D000075202:Contraindications; D003876:Dermatitis, Atopic / Q000628:therapy / Q000662:veterinary*; D003888:Desensitization, Immunologic / Q000662:veterinary*; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D006801:Humans; D007271:Injections, Intradermal / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000662:veterinary; D012955:Societies, Medical; D014481:United States
chemical_list: D000485:Allergens